Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) are both prominent names in the Medtech space.
Keep Reading →
August 10 - Hedge Funds, News
Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics...
Keep Reading →
August 10 - Hedge Funds, News
Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 billion, above analysts' average estimate of about...
Keep Reading →
August 10 - Hedge Funds, News
Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics...
Keep Reading →
August 4 - Hedge Funds, News
Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics...
Keep Reading →
July 27 - Hedge Funds, News
RBC Wealth Management noted that the consensus 2026 earnings growth forecast for the S&P 500 saw an increase from 13.6% at the start of the year to 23.3% by the end of June.
Keep Reading →
July 10 - Hedge Funds, News
TheFly reported on July 6 that Evercore ISI analyst Vijay Kumar reduced the firm’s price target on Abbott Laboratories to $112 from $120 while maintaining an Outperform rating...
Keep Reading →
July 8 - News
The U.S. healthcare sector has lagged behind the entire market for three consecutive years, with returns of just 0.3% in 2023, 0.9% in 2024, and 12.5% in 2025.
Keep Reading →
July 7 - Hedge Funds, News
On May 10, Bloomberg reported that brain-computer interfaces are transitioning from experimental to early implementation, allowing users to control computers, robotic arms, and...
Keep Reading →
June 25 - Hedge Funds, News
On June 17, 2026, the Fed held interest rates steady as expected, but new Chair Kevin Warsh's first policy statement stripped out forward guidance on future rate moves, blindsiding...
Keep Reading →
June 24 - Hedge Funds, News
In May, Forbes reported that retail investors are continuing to put money into the market even as geopolitical tensions increase and market volatility edges higher.
Keep Reading →
June 17 - Dividend Stocks, Hedge Funds, News
On June 8, Reuters reported that Citigroup raised its 2026 year-end target for the S&P 500 index to more than 8,100, thanks to corporate earnings and AI-driven growth.
Keep Reading →
June 13 - Hedge Funds, News
Longevity stocks are getting more attention as investors look for companies tied to longer lifespans, healthier aging, and rising demand for care.
Keep Reading →
June 11 - Hedge Funds, News
Value stocks are on the move, after years of underperformance, amid heightened market volatility and a shift away from mega-cap concentration.
Keep Reading →
June 9 - Hedge Funds, News
Abbott Laboratories (NYSE:ABT) is one of the best healthcare stocks to buy with highest upside potential.
Keep Reading →
June 9 - News
As per Columbia Threadneedle Investments, the broader markets seem to be significantly resilient amidst the Middle East conflict.
Keep Reading →
June 8 - Hedge Funds, News
On June 1, Tom Lee, Fundstrat managing partner and head of research, and Fundstrat Capital CIO, appeared on CNBC’s ‘Squawk Box’ to talk about the latest market trends, the...
Keep Reading →
June 7 - Hedge Funds, News
In this article, we will look at the stocks Jim Cramer discussed during his recent rally discussion in several AI-related stocks.
Keep Reading →
June 3 - Hedge Funds, News
One of the key conclusions in EY’s 19th annual Pulse of the MedTech Industry Report is that the global medical technology market has moved from a period of post-pandemic turbulence...
Keep Reading →
May 25 - Hedge Funds, News
In this article, we will look at the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up for this market.
Keep Reading →
May 13 - Hedge Funds, News
Abbott Laboratories (NYSE:ABT) is one of the best medical device stocks to invest in right now. Abbott Laboratories (NYSE:ABT) announced on April 28 that it received the U.S.
Keep Reading →
May 1 - News
On April 27, Tom Lee, Fundstrat Capital Chief Investment Officer and Bitmine Immersion Technologies Chairman, appeared on CNBC's ‘Power Lunch’ to discuss the outlook for equity...
Keep Reading →
April 29 - Hedge Funds, News
A stock index is considered to be in a bear market when its closing price falls at least 20% from its most recent high.
Keep Reading →
April 24 - Hedge Funds, News
Oversold blue chip stocks are drawing a closer look, but not just because they have fallen.
Keep Reading →
April 14 - Hedge Funds, News
In this article, we will look at the stocks on Jim Cramer’s game plan as he shared his take on the market post-Iran-U.S. ceasefire talks.
Keep Reading →
April 13 - Hedge Funds, News
According to an April 6 report by CNBC, if the Iran war drags on longer than expected, investors may want to look at defensive stocks that pay dividends, according to Jefferies...
Keep Reading →
April 6 - Dividend Stocks, Hedge Funds, News
On March 24, Reuters reported that Barclays raised its 2026 year-end S&P 500 target on the heels of robust corporate earnings, thanks to the broader technology sector and resilience...
Keep Reading →
March 25 - Hedge Funds, News
Abbott Laboratories (NYSE:ABT) ranks among the best most active stocks to buy right now.
Keep Reading →
March 24 - News
Recent market volatility has unnerved investors, but not all analysts are turning negative just yet.
Keep Reading →
March 23 - Hedge Funds, News
Abbott Laboratories (NYSE:ABT) is one of Goldman Sachs top healthcare stocks.
Keep Reading →
March 15 - News
The healthcare sector, long seen as a laggard amid the artificial intelligence boom, is beginning to turn the corner.
Keep Reading →
March 14 - Hedge Funds, News
On February 2, the price target on Abbott Laboratories (NYSE:ABT) was reduced from $169 to $142 by Barclays analyst Matt Miksic.
Keep Reading →
February 23 - News
The Healthcare Equipment segment is one of the areas across the broader healthcare landscape that carries immense innovation prospects and also offers a defensive play.
Keep Reading →
February 23 - Hedge Funds, News
Abbott Laboratories (NYSE:ABT) is one of the Best Dip Stocks to Buy According to Hedge Funds.
Keep Reading →
February 20 - News
On February 17, Mohamed El-Erian, Chief Economic Advisor at Allianz, appeared on a CNBC Television interview to discuss the way forward amidst the volatility.
Keep Reading →
February 19 - Hedge Funds, News
Abbott Laboratories (NYSE:ABT) is one of the best 52-week low blue-chip stocks to buy right now.
Keep Reading →
February 8 - News
The S&P 500 has performed exceedingly well over the past two years, powering to all-time highs amid easing inflation and the artificial intelligence boom.
Keep Reading →
February 7 - Hedge Funds, News
A Reuters report said Abbott Laboratories (NYSE:ABT) warned that its current-quarter profit would come in below expectations after the company also fell short of Wall Street’...
Keep Reading →
February 3 - News
Dividend aristocrats are companies that have raised their dividends every year for at least 25 years.
Keep Reading →
January 31 - Dividend Stocks, Hedge Funds, News
On January 27, Sherry Paul, a senior portfolio manager at Morgan Stanley, appeared on a CNBC Television interview to discuss the state of the markets and concerns about volatility...
Keep Reading →
January 30 - Hedge Funds, News
On January 23, Larry Biegelsen from Wells Fargo maintained an Overweight rating on Abbott Laboratories (NYSE:ABT).
Keep Reading →
January 30 - News
It is challenging to identify segments within the markets that appear to be defensive plays, yet offer innovation potential.
Keep Reading →
January 30 - Hedge Funds, News
Pharma giant Abbott Laboratories (NYSE:ABT)’s shares are down 15.9% over the past year and 12% year-to-date.
Keep Reading →
January 28 - News
In a recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed OpenAI's ChatGPT and business applications.
Keep Reading →
January 27 - News
On January 23, Evercore ISI trimmed its price target on Abbott Laboratories (NYSE:ABT) to $138 from $144. However, it kept an Outperform rating.
Keep Reading →
January 26 - News
Savita Subramanian, the firm’s head of US equity and quant strategy, pointed to a familiar timing pattern.
Keep Reading →
January 25 - Dividend Stocks, Hedge Funds, News
TheFly reported on January 9 that Bernstein analyst Lee Hambright raised ABT’s price target to $154 from $150, while maintaining an Outperform rating on the stock.
Keep Reading →
January 18 - News
As of early 2026, the U.S. economy is in a fragile “stagflation-lite” phase, balancing resilient growth against an elevated risk of recession.
Keep Reading →
January 17 - Lists, News
On December 22, Abbott Laboratories (NYSE:ABT) said the US Food and Drug Administration has approved the company’s Volt™ PFA System to treat patients with atrial fibrillation...
Keep Reading →
December 30 - News
For most drugmakers, the US is the largest single market. Prices there are often close to three times higher than in other developed countries.
Keep Reading →
December 29 - Dividend Stocks, Hedge Funds, News